Ananda Chairman Funds Next Clinical Trials in Latest Financing Round

September 09, 2024 07:20 PM BST | By Team Kalkine Media
 Ananda Chairman Funds Next Clinical Trials in Latest Financing Round
Image source: shutterstock

Ananda Developments Plc (AQSE:ANA) announced that its chairman, Charles Morgan, is leading a significant £2.15 million fundraising effort, contributing over £2 million at a share price of 0.3p. This substantial contribution is part of the company’s initiative to advance its work in inflammatory pain treatment.

In addition to Morgan’s financial input, both he and the company's chief executive, Melissa Sturgess, have agreed to capitalise the unsecured debt owed to them. Morgan’s debt stands at around £1.9 million, while Sturgess will capitalise approximately £10,000. This debt conversion into shares further strengthens the company’s financial position. A retail offer via the Winterflood WRAP platform is also underway to raise up to £100,000, providing additional support to the fundraising campaign.

The funds raised are earmarked for several key areas in Ananda's ongoing development of its MRX1 drug candidate. Specifically, the company plans to use the money for manufacturing MRX1 to support its Phase II studies for chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis. Additionally, the proceeds will fund a pharmacokinetic study for MRX1 in Australia and contribute to general working capital needs.

Following the completion of the fundraising and debt capitalisation, Morgan will hold 57.43% of Ananda's shares in issue, while Sturgess will hold 9.94%. This significant equity stake solidifies Morgan’s position as the largest shareholder and reflects his continued commitment to the company’s growth and its clinical objectives.

Sturgess expressed confidence in the company’s future, stating that the substantial equity support from Morgan and other contributors places Ananda in a strong position to move forward with its clinical trials. The focus now will be on reaching important milestones, which include progressing MRX1 through trials, securing licensing agreements, and eventually bringing the drug into the NHS and other licensed markets.

Overall, the fundraising efforts and debt restructuring are expected to play a crucial role in advancing Ananda’s work in inflammatory pain treatment, with the company focused on bringing its MRX1 candidate closer to market approval and clinical success.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next